Markets / Nifty Healthcare

Nifty Healthcare stocks

Updated 15:08

Nifty Healthcare 16,659.85 (+0.48%) · The 20 stocks in the index (sectoral index, official list from NSE Indices). All indices →

Stocks
20
Advancing
13
Declining
7
Average change
+0.62%
Total market cap (₹ Cr)
22,29,861

Top gainers

StockPriceChange
Glenmark Pharmaceuticals2,506.80+4.10%
Abbott India26,720.00+3.57%
Max Healthcare Institute922.85+3.05%
Mankind Pharma2,521.30+1.87%
Apollo Hospitals Enterprise8,562.50+1.45%

Top losers

StockPriceChange
Zydus Lifesciences1,195.60-3.63%
Alkem Laboratories5,179.00-1.09%
Laurus Labs2,302.90-0.87%
Divi's Laboratories10,033.00-0.31%
Dr. Reddy's Laboratories1,365.60-0.20%

All Nifty Healthcare stocks

StockPriceChange1 month1 yearRSI (14)P/EROEMarket cap (₹ Cr)
Sun Pharmaceutical Industries1,776.40+0.37%-1.7%+4.5%45.638.912.3%4,26,212
Divi's Laboratories10,033.00-0.31%+8.8%+55.1%69.7113.514.0%2,65,875
Torrent Pharmaceuticals4,695.60+0.98%-2.5%+29.3%48.484.111.6%1,78,602
Laurus Labs2,302.90-0.87%+17.1%+147.1%68.992.922.1%1,24,426
Apollo Hospitals Enterprise8,562.50+1.45%+3.8%+7.6%59.258.922.0%1,23,129
Zydus Lifesciences1,195.60-3.63%+8.3%+22.4%69.326.416.7%1,19,321
Dr. Reddy's Laboratories1,365.60-0.20%+13.4%+6.5%75.140.77.2%1,14,028
Cipla1,397.10+0.01%+3.9%-11.8%63.739.08.2%1,12,865
Mankind Pharma2,521.30+1.87%-2.4%+2.4%56.846.312.8%1,04,130
Aurobindo Pharma1,704.90+0.61%+1.1%+54.8%56.826.49.8%98,100
Lupin2,017.20+0.06%-0.8%+4.8%52.316.724.6%92,236
Max Healthcare Institute922.85+3.05%-4.8%-24.5%51.565.012.2%89,822
Glenmark Pharmaceuticals2,506.80+4.10%+3.3%+32.8%60.947.314.2%70,742
Alkem Laboratories5,179.00-1.09%+0.3%-4.4%56.028.715.6%61,915
Fortis Healthcare787.90+0.30%+0.1%-25.4%52.456.810.6%59,483
Biocon342.65-0.10%-7.5%-4.8%41.2112.71.5%55,838
Gland Pharma3,157.40-0.05%+9.7%+64.4%62.746.110.9%52,084
IPCA Laboratories1,971.40+1.09%+0.4%+50.3%53.738.216.2%50,014
Krishna Institute of Medical Sciences739.05+1.17%-0.6%+2.0%57.9151.89.1%31,040
Abbott India26,720.00+3.57%-4.0%-13.4%47.4–––

Information only, not investment advice.